Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office Jan 9, 2019
Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan Dec 31, 2018
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Dec 20, 2018
Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares Oct 11, 2018
Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares Oct 4, 2018
